Literature DB >> 17763938

The organization and funding of the treatment of end-stage renal disease in Australia.

Anthony Harris1.   

Abstract

Treatment rates for end-stage renal disease have risen over the last 25 years in Australia, from 3,181 patients in 1981 to 14,221 patients (707 per million) in 2004. Access to dialysis services is largely through the national public insurance system, with more than 85% of services provided by public hospitals for outpatient (68%) or home-based (32%) care. Annual payment rates per patient are around AU$53,500 for hemodialysis (78% of patients). Total recurrent health expenditure on all chronic kidney disease was AU$647 million, or 1.3% of the total recurrent health expenditure that could be allocated by disease.

Entities:  

Mesh:

Year:  2007        PMID: 17763938     DOI: 10.1007/s10754-007-9018-7

Source DB:  PubMed          Journal:  Int J Health Care Finance Econ        ISSN: 1389-6563


  6 in total

1.  Using computerised patient-level costing data for setting DRG weights: the Victorian (Australia) cost weight studies.

Authors:  T Jackson
Journal:  Health Policy       Date:  2001-05       Impact factor: 2.980

Review 2.  End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).

Authors:  Avi Dor; Mark V Pauly; Margaret A Eichleay; Philip J Held
Journal:  Int J Health Care Finance Econ       Date:  2007-09

3.  Nocturnal haemodialysis: an Australian cost comparison with conventional satellite haemodialysis.

Authors:  John Wm Agar; Richard J Knight; Rosemary E Simmonds; Janeane M Boddington; Claire M Waldron; Christine A Somerville
Journal:  Nephrology (Carlton)       Date:  2005-12       Impact factor: 2.506

4.  Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access.

Authors:  Helen Lee; Braden Manns; Ken Taub; William A Ghali; Stafford Dean; David Johnson; Cam Donaldson
Journal:  Am J Kidney Dis       Date:  2002-09       Impact factor: 8.860

5.  An epidemic of renal failure among Australian Aboriginals.

Authors:  J L Spencer; D T Silva; P Snelling; W E Hoy
Journal:  Med J Aust       Date:  1998-06-01       Impact factor: 7.738

6.  End-stage renal disease in the Northern Territory: current and future treatment costs.

Authors:  Jiqiong You; Wendy Hoy; Yuejen Zhao; Carol Beaver; Kathy Eagar
Journal:  Med J Aust       Date:  2002-05-20       Impact factor: 7.738

  6 in total
  5 in total

Review 1.  End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).

Authors:  Avi Dor; Mark V Pauly; Margaret A Eichleay; Philip J Held
Journal:  Int J Health Care Finance Econ       Date:  2007-09

Review 2.  Belgium's mixed private/public health care system and its impact on the cost of end-stage renal disease.

Authors:  Wim Van Biesen; Norbert Lameire; Patrick Peeters; Raymond Vanholder
Journal:  Int J Health Care Finance Econ       Date:  2007-09

3.  An economic assessment model for in-center, conventional home, and more frequent home hemodialysis.

Authors:  Paul Komenda; Meghan B Gavaghan; Susan S Garfield; Amy W Poret; Manish M Sood
Journal:  Kidney Int       Date:  2011-10-12       Impact factor: 10.612

Review 4.  Continuous ambulatory peritoneal dialysis: perspectives on patient selection in low- to middle-income countries.

Authors:  Nicola Wearne; Kajiru Kilonzo; Emmanuel Effa; Bianca Davidson; Peter Nourse; Udeme Ekrikpo; Ikechi G Okpechi
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-01-04

5.  'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study.

Authors:  Charlotte Logeman; Yeoungjee Cho; Benedicte Sautenet; Gopala K Rangan; Talia Gutman; Jonathan Craig; Albert Ong; Arlene Chapman; Curie Ahn; Helen Coolican; Juliana Tze-Wah Kao; Ron T Gansevoort; Ronald Perrone; Tess Harris; Vincent Torres; Kevin Fowler; York Pei; Peter Kerr; Jessica Ryan; David Johnson; Andrea Viecelli; Clair Geneste; Hyunsuk Kim; Yaerim Kim; Martin Howell; Angela Ju; Karine E Manera; Armando Teixeira-Pinto; Gayathri Parasivam; Allison Tong
Journal:  BMJ Open       Date:  2020-10-10       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.